Anthos Therapeutics

What Anthos Therapeutics does

Anthos Therapeutics is a clinical-stage biopharmaceutical company founded in 2019 by Blackstone Life Sciences and Novartis to develop therapies for cardiovascular and metabolic diseases, with an exclusive focus on abelacimab — a novel, fully human monoclonal antibody that selectively binds Factor XI and its activated form (Factor XIa) to provide hemostasis-sparing anticoagulation. The lead asset is being developed for two parallel indications: stroke and systemic embolism prevention in atrial fibrillation (AF) patients unsuitable for current anticoagulants, and treatment of cancer-associated thrombosis (VTE). Abelacimab differentiates from existing direct oral anticoagulants (DOACs) and low-molecular-weight heparin through its mechanism (mimicking natural Factor XI deficiency), once-monthly subcutaneous dosing achieving ~99% Factor XI inhibition, dual IV/subcutaneous administration flexibility, and absence of cytochrome P450-mediated drug-drug interactions.

The clinical program is one of the largest and longest head-to-head anticoagulant development efforts to date. The AZALEA-TIMI 71 Phase 2 study enrolled 1,287 patients across 95 global sites and was stopped early by the IDMC in 2023 for overwhelming efficacy (67% reduction in major or CRNM bleeding versus rivaroxaban), with results published in the New England Journal of Medicine in January 2025. The Phase 3 program comprises LILAC-TIMI 76 (~1,900 patients, 400+ sites) in AF and the ASTER/MAGNOLIA studies (~2,700 patients across 220 sites in 23+ countries) in cancer-associated thrombosis — readouts are expected in H2 2026. The FDA granted two Fast Track Designations in 2022.

Anthos generated no commercial revenue as a clinical-stage entity; the company operated with 11-50 employees and was funded initially by a $250M Blackstone Life Sciences investment. In February 2025, Novartis announced an agreement to reacquire Anthos for up to $3.1 billion ($925M upfront plus milestones), completing the transaction in April 2025. Following the acquisition, Anthos operates as a Novartis company, with future abelacimab commercialization flowing through Novartis's global cardiovascular sales infrastructure and specialty distribution channels.

Name

Anthos Therapeutics

Legal name

Anthos Therapeutics, Inc.

Website

https://anthostherapeutics.com

Company type

Private

Founded year

2019

Operating status

Acquired

Headcount range

11–50 employees

Short description

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a novel Factor XI-targeting monoclonal antibody for atrial fibrillation and cancer-associated thrombosis; acquired by Novartis in April 2025 for up to $3.1 billion.

Ownership category

akta.pro rank

Product category

Cardiovascular Biopharmaceuticals

NAICS

Other Scientific and Technical Consulting Services (541690), Medical and Diagnostic Laboratories (62151)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAIAHAD

Alpha-1 Antitrypsin (AAT) Therapies

Healthcare & Life Sciences/Pharmaceuticals/Plasma-Derived Therapies

Keywords

• Cardiovascular therapeutics
• Monoclonal antibody development
• Anticoagulant drug development
• Factor XI inhibitors
• Clinical-stage biopharmaceuticals

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Licensing and Royalties: Anthos Therapeutics was acquired by Novartis in April 2025 for up to $3.1 billion (including $925M upfront), with potential milestone payments. Novartis holds exclusive rights to develop, manufacture, and commercialize abelacimab globally. Future revenue will come from pharmaceutical product sales through Novartis's commercial infrastructure.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a fully human monoclonal antibody Factor XI inhibitor for the prevention and treatment of thrombotic diseases. The company's lead clinical programs target atrial fibrillation, cancer-associated thrombosis, and post-surgical venous thromboembolism prevention, with Phase 3 trials (AZALEA-TIMI 71 and OCEANIC-AF) underway to support regulatory approval and commercialization.

Product overview

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing innovative therapies for cardiovascular metabolic diseases. The company's lead product is abelacimab, a novel Factor XI inhibitor (fully human monoclonal antibody) in late-stage clinical development for the prevention of stroke and systemic embolism in patients with atrial fibrillation and for the treatment of cancer-associated thrombosis. Abelacimab is administered via intravenous infusion for acute indications and subcutaneous monthly injections for chronic settings. The company was acquired by Novartis in April 2025.

Differentiator

Problem solved

Functional benefit

Products and services

• Abelacimab Abelacimab is a fully human monoclonal antibody Factor XI inhibitor being developed by Anthos Therapeutics for the prevention and treatment of thrombotic diseases. It is designed to provide hemostasis-sparing anticoagulation with both intravenous and once-monthly subcutaneous dosing options, and is being evaluated in Phase 3 trials (AZALEA-TIMI 71 and OCEANIC-AF) for atrial fibrillation, cancer-associated thrombosis, and post-surgical venous thromboembolism prevention.

Quantifiable outcome

• 67-62% reduction in major or clinically relevant non-major bleeding vs rivaroxaban
• +6 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• NovartiscoreStrategic or Co-development Partner · 3 April 2025Novartis originally created and spun out Anthos Therapeutics in 2019 via Blackstone Life Sciences. Novartis retained rights and reacquired Anthos in February 2025 for $925M upfront (up to $3.1B total) to bring abelacimab back into its cardiovascular pipeline. Novartis is the parent company following the acquisition.
• ISPORminorGTM or Marketing Partner · 6 May 2024Health economics conference where first-ever cost-effectiveness analysis of abelacimab was presented, demonstrating $50,000 potential savings per patient over lifetime vs rivaroxaban.
• TIMI Study GroupcoreStrategic or Co-development PartnerAcademic research organization leading the AZALEA-TIMI 71 and LILAC-TIMI 76 clinical trials. Dr. Christian T. Ruff is Principal Investigator and Director of General Cardiology at Brigham and Women's Hospital. The partnership provides clinical trial expertise and academic credibility.
• StopAfib.org (American Foundation for Women's Health)minorGTM or Marketing PartnerPatient advocacy partnership for atrial fibrillation awareness and education. Mellanie True Hills, founder and CEO, serves as patient advocate supporting clinical trial enrollment and patient education.
• National Blood Clot Alliance (StopTheClot)minorGTM or Marketing PartnerPatient advocacy partnership focused on blood clot awareness, risk recognition, and prevention education.
• MedscapeminorGTM or Marketing PartnerHealthcare professional education partnership for continuing medical education programs featuring abelacimab clinical data and Factor XI inhibition scientific content.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Pfizer: Pfizer co-markets Eliquis (apixaban) with BMS, the leading direct oral anticoagulant and the comparator in Anthos's ASTER study. It is a broad incumbent defining standard of care in the indications abelacimab targets.
• Boehringer Ingelheim: Boehringer Ingelheim markets Pradaxa (dabigatran), one of the established direct oral anticoagulants used in AF and VTE. It is a broad incumbent competing for the same patient populations abelacimab is being developed for.
• Daiichi Sankyo: Daiichi Sankyo markets Lixiana/Savaysa (edoxaban), a DOAC approved for AF and VTE indications overlapping with abelacimab's development program. It is a broad incumbent in the anticoagulant market.

Emerging players

• Alexion (AstraZeneca Rare Disease): Alexion acquired Portola Pharmaceuticals and markets AndexXa (andexanet alfa), a Factor Xa inhibitor reversal agent. It operates in the adjacent anticoagulant management space where abelacimab's bleeding-sparing profile could shift utilization.

Direct peers

• Johnson & Johnson: J&J is the co-developer of milvexian with BMS and a co-marketer of Xarelto (rivaroxaban). It is directly comparable to Anthos as a Factor XIa inhibitor developer and as a partner in the standard-of-care DOAC franchise.
• Bristol Myers Squibb: BMS, partnered with Johnson & Johnson, is developing milvexian, an oral Factor XIa inhibitor in late-stage trials, and co-markets Eliquis (apixaban), the DOAC market leader. BMS is a direct FXI-class rival and a major incumbent in the anticoagulant space.
• Bayer: Bayer is developing asundexian, an oral small-molecule Factor XIa inhibitor, and markets Xarelto (rivaroxaban), the direct comparator in Anthos's AZALEA-TIMI 71 study. It is the most direct head-to-head competitor in the Factor XI class and the incumbent in the relevant DOAC indication.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/anthos-therapeutics
• Xx.com/Anthos_Tx

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anthos Therapeutics